Biogen has announced that the European Commission (EC) has granted marketing authorisation for Vumerity® (diroximel fumarate) to treat adults with relapsing-remitting multiple sclerosis (MS).
Banner Life Sciences LLC (Banner), a privately held specialty pharmaceutical company, today announced that BAFIERTAMâ„¢ (monomethyl fumarate), a novel fumarate for the treatment of relapsing forms of multiple sclerosis (MS) in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, has commercially launched and is now available in the U.S.
HIGH POINT, N.C.--(BUSINESS WIRE)--Banner Life Sciences LLC (Banner), a privately held specialty pharmaceutical company, today announced that BAFIERTAM™ (monomethyl fumarate), a novel fumarate for adults for the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, will be commercially available in the U.S. September 1, 2020. BAFIERTAM was approved by the U.S. Food and Drug Administration (FDA) on April 28, 2020.
Banner Life Sciences LLC (Banner), a privately held specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) granted final approval of BAFIERTAM™ (monomethyl fumarate) delayed-release capsules for the treatment of relapsing forms of multiple sclerosis (MS).
HIGH POINT, N.C.--(BUSINESS WIRE)--Banner Life Sciences LLC (Banner), a privately held specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) granted final approval of BAFIERTAM™ (monomethyl fumarate) delayed-release capsules for the treatment of relapsing forms of multiple sclerosis (MS).
Alkermes and Biogen announce new MS drug application for FDA